Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that it has launched Rhopressa in the United States. Rhopressa is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa through their local pharmacies across the nation.
“We are pleased to announce the availability in the United States of Rhopressa, the first new drug class in more than two decades for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. Our national sales force is fully trained, deployed, and already providing product information and samples to physicians. Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D program coverage beginning in 2019 are in the final stages of being executed,” said Vicente Anido, Jr., Ph.D., chairman and CEO.
(Source: Aerie Pharmaceuticals, Inc.)
Filed Under: Drug Discovery